Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: A systematic review of randomized controlled trials

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3423-3434

  Vouloumanou, Evridiki K ^a   Rafailidis, Petros I ^a,c   Kazantzi, Maria S ^a   Athanasiou, Stavros ^d   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antibiotics; DMSA; Renal scars; Sequential treatment; Urinary tract infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFIXIME; CEFTIBUTEN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NETILMICIN; NITROFURANTOIN; NITROXOLINE; TEMOCILLIN;

ACUTE PYELONEPHRITIS; ANTIMICROBIAL THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; INJECTION SITE PAIN; KIDNEY SCAR; LOADING DRUG DOSE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; REINFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADOLESCENT; ADULT; CHILD; FEMALE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDLINE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PYELONEPHRITIS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; META-ANALYSIS AS TOPIC; PUBMED; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 62349096032     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802550679     Document Type: Review

References (45)

1. Czaja CA, Scholes D, Hooton TM, et al. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45:273-280 (Pubitemid 47101021)
2. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol 2003;13:144-150
3. Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2007; CD003772
4. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 2005;23:1123-1142 (Pubitemid 41637754)
5. Kim K, Lee CC, Rhee JE, et al. The effects of an institutional care map on the admission rates and medical costs in women with acute pyelonephritis. Acad Emerg Med 2008;15:319-323
6. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-470
7. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 2005;71:933-942 (Pubitemid 40321958)
8. Safrin S, Siegel D, Black D. Pyelonephritis in adult women: inpatient versus outpatient therapy. Am J Med 1988;85:793-798 (Pubitemid 19020523)
9. Hoberman A, Wald ER, Hickey RW, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999;104:79-86 (Pubitemid 29315851)
10. Montini G, Toffolo A, Zucchetta P, et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ. 2007;335:386 (Pubitemid 47359317)
11. Ahmetagic S, Jusufovic E, Cengic D, et al. [Analysis of amoxicillin-clavulanic acid (Xiclav) efficacy and the possibility of early switch from parenteral to oral therapy in the treatment of infections]. Med Arh 2003;57:263-266
12. McCracken GH. New era for orally administered antibiotics: use of sequential parenteral-oral antibiotic therapy for serious infectious diseases of infants and children. Pediatr Infect Dis J 1987;6:951-953 (Pubitemid 17151054)
13. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 1996;12:195-208 (Pubitemid 26195520)
14. Bouissou F, Munzer C, Decramer S, et al. Prospective, randomized trial comparing short and long intravenous antibiotic treatment of acute pyelonephritis in children: dimercaptosuccinic acid scintigraphic evaluation at 9 months. Pediatrics 2008;121:553-560
15. Noorbakhsh S, Lari AR, Masjedian F, et al. Comparison of intravenous aminoglycoside therapy with switch therapy to cefixime in urinary tract infections. Saudi Med J 2004;25:1513-1515 (Pubitemid 39429624)
16. Benador D, Neuhaus TJ, Papazyan JP, et al. Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring. Arch Dis Child 2001;84:241-246 (Pubitemid 32250832)
17. Levtchenko E, Lahy C, Levy J, et al. Treatment of children with acute pyelonephritis: a prospective randomized study. Pediatr Nephrol 2001;16:878-884 (Pubitemid 33040645)
18. Vilaichone A, Watana D, Chaiwatanarat T. Oral ceftibuten switch therapy for acute pyelonephritis in children. J Med Assoc Thai 2001;84(Suppl 1):61-67 (Pubitemid 32929081)
19. François P, Bensman A, Bégué P, et al. Assessment of the efficacy and cost efficiency of two strategies in the treatment of acute pyelonephritis in children: oral cefixime or parenteral ceftriaxone after an initial i.v. combination therapy. Médecine et Maladies Infectieuses 1997;27:667-673 (Pubitemid 27322176)
20. Bailey RR, Begg EJ, Smith AH, et al. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clin Nephrol 1996;46:183-186 (Pubitemid 26306528)
21. Regnier B. [Comparative study of intravenous ceftriaxone followed by oral cefixime versus ceftriaxone alone in the treatment of severe upper urinary tract infections]. Presse Med 1989;18:1617-1621
22. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev 2007;CD003237 (Pubitemid 351805309)
23. Bhatnagar V, Mitra DK, Agarwala S, et al. The role of DMSA scans in evaluation of the correlation between urinary tract infection, vesicoureteric reflux, and renal scarring. Pediatr Surg Int 2002;18:128-134 (Pubitemid 36014865)
24. Jakobsson B, Berg U, Svensson L. Renal scarring after acute pyelonephritis. Arch Dis Child 1994;70:111-115 (Pubitemid 24088962)
25. MacKenzie JR. A review of renal scarring in children. Nucl Med Commun 1996;17:176-190 (Pubitemid 26100340)
26. Raz R, Sakran W, Chazan B, et al. Long-term follow-up of women hospitalized for acute pyelonephritis. Clin Infect Dis 2003;37:1014-1020 (Pubitemid 37323654)
27. Smellie JM, Shaw PJ, Prescod NP, et al. 99mTc dimercaptosuccinic acid (DMSA) scan in patients with established radiological renal scarring. Arch Dis Child 1988;63:1315-1319 (Pubitemid 18258764)
28. Ahmed M, Eggleston D, Kapur G, et al. Dimercaptosuccinic acid (DMSA) renal scan in the evaluation of hypertension in children. Pediatr Nephrol 2008;23:435-438
29. Jahnukainen T, Chen M, Celsi G. Mechanisms of renal damage owing to infection. Pediatr Nephrol 2005;20:1043-1053 (Pubitemid 41001542)
30. el-Khatib M, Packham DK, Becker GJ, et al. Pregnancy-related complications in women with reflux nephropathy. Clin Nephrol 1994;41:50-55
31. Hollowell JG. Outcome of pregnancy in women with a history of vesico-ureteric reflux. BJU Int. 2008; 102: 780-784
32. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-758 (Pubitemid 30256361)
33. Jackson MA, Nelson JD. Etiology and medical management of acute suppurative bone and joint infections in pediatric patients. J Pediatr Orthop 1982;2:313-323
34. Tuomanen EI, Powell KR, Marks MI, et al. Oral chloramphenicol in the treatment of Haemophilus influenzae meningitis. J Pediatr 1981;99:968-974 (Pubitemid 12240131)
35. Hagaman JT, Yurkowski P, Trott A, et al. Getting physicians to make "the switch": the role of clinical guidelines in the management of community-acquired pneumonia. Am J Med Qual 2005;20:15-21
36. Powell J, Tarnow KG, Perucca R. The relationship between peripheral intravenous catheter indwell time and the incidence of phlebitis. J Infus Nurs 2008;31:39-45
37. Uslusoy E, Mete S. Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study. J Am Acad Nurse Pract 2008;20:172-180
38. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):13 (Pubitemid 34756640)
39. Pablos AI, Escobar I, Albinana S, et al. Evaluation of an antibiotic intravenous to oral sequential therapy program. Pharmacoepidemiol Drug Saf 2005;14:53-59 (Pubitemid 40089579)
40. Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 1999;159:53-58 (Pubitemid 29044120)
41. Pangon B, Chaplain C. [Acute pyelonephritis: bacteriological data and general course of germ resistance]. Pathol Biol (Paris) 2003;51:503-507
42. Trinchiere A. [Role of levofloxacin in the treatment of urinary tract infections]. Arch Ital Urol Androl 2001;73:105-113
43. Schaeffer AJ. The expanding role of fluoroquinolones. Dis Mon 2003;49:129-147 (Pubitemid 36350780)
44. The use of systemic fluoroquinolones. Pediatrics 2006;118:1287-1292 (Pubitemid 46090075)
45. Cuzzolin L, Fanos V. Safety of fluoroquinolones in paediatrics. Expert Opin Drug Saf 2002;1:319-324